145 related articles for article (PubMed ID: 20457621)
1. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.
Stacchiotti S; Negri T; Palassini E; Conca E; Gronchi A; Morosi C; Messina A; Pastorino U; Pierotti MA; Casali PG; Pilotti S
Mol Cancer Ther; 2010 May; 9(5):1286-97. PubMed ID: 20457621
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib malate in solitary fibrous tumor (SFT).
Stacchiotti S; Negri T; Libertini M; Palassini E; Marrari A; De Troia B; Gronchi A; Dei Tos AP; Morosi C; Messina A; Pilotti S; Casali PG
Ann Oncol; 2012 Dec; 23(12):3171-3179. PubMed ID: 22711763
[TBL] [Abstract][Full Text] [Related]
3. Response to sunitinib malate in advanced alveolar soft part sarcoma.
Stacchiotti S; Tamborini E; Marrari A; Brich S; Rota SA; Orsenigo M; Crippa F; Morosi C; Gronchi A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2009 Feb; 15(3):1096-104. PubMed ID: 19188185
[TBL] [Abstract][Full Text] [Related]
4. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.
Stacchiotti S; Tortoreto M; Bozzi F; Tamborini E; Morosi C; Messina A; Libertini M; Palassini E; Cominetti D; Negri T; Gronchi A; Pilotti S; Zaffaroni N; Casali PG
Clin Cancer Res; 2013 Sep; 19(18):5192-201. PubMed ID: 23888069
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Stacchiotti S; Tortoreto M; Baldi GG; Grignani G; Toss A; Badalamenti G; Cominetti D; Morosi C; Dei Tos AP; Festinese F; Fumagalli E; Provenzano S; Gronchi A; Pennacchioli E; Negri T; Dagrada GP; Spagnuolo RD; Pilotti S; Casali PG; Zaffaroni N
Eur J Cancer; 2014 Nov; 50(17):3021-8. PubMed ID: 25269954
[TBL] [Abstract][Full Text] [Related]
6. Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study.
Stacchiotti S; Simeone N; Lo Vullo S; Morosi C; Greco FG; Gronchi A; Barisella M; Collini P; Zaffaroni N; Dagrada GP; Frezza AM; Mariani L; Casali PG
Eur J Cancer; 2019 Jan; 106():225-233. PubMed ID: 30528807
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.
Stacchiotti S; Negri T; Zaffaroni N; Palassini E; Morosi C; Brich S; Conca E; Bozzi F; Cassinelli G; Gronchi A; Casali PG; Pilotti S
Ann Oncol; 2011 Jul; 22(7):1682-1690. PubMed ID: 21242589
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours.
Spagnuolo RD; Brich S; Bozzi F; Conca E; Castelli C; Tazzari M; Maestro R; Brenca M; Gualeni AV; Gloghini A; Stacchiotti S; Pierotti MA; Pilotti S; Negri T
Oncotarget; 2016 Jul; 7(29):45015-45026. PubMed ID: 27304187
[TBL] [Abstract][Full Text] [Related]
9. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy.
Tazzari M; Negri T; Rini F; Vergani B; Huber V; Villa A; Dagrada P; Colombo C; Fiore M; Gronchi A; Stacchiotti S; Casali PG; Pilotti S; Rivoltini L; Castelli C
Br J Cancer; 2014 Sep; 111(7):1350-62. PubMed ID: 25101565
[TBL] [Abstract][Full Text] [Related]
10. Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene.
Mudry P; Slaby O; Neradil J; Soukalova J; Melicharkova K; Rohleder O; Jezova M; Seehofnerova A; Michu E; Veselska R; Sterba J
BMC Cancer; 2017 Feb; 17(1):119. PubMed ID: 28183292
[TBL] [Abstract][Full Text] [Related]
11. Activity of sunitinib in extraskeletal myxoid chondrosarcoma.
Stacchiotti S; Pantaleo MA; Astolfi A; Dagrada GP; Negri T; Dei Tos AP; Indio V; Morosi C; Gronchi A; Colombo C; Conca E; Toffolatti L; Tazzari M; Crippa F; Maestro R; Pilotti S; Casali PG
Eur J Cancer; 2014 Jun; 50(9):1657-64. PubMed ID: 24703573
[TBL] [Abstract][Full Text] [Related]
12. Response to chemotherapy of solitary fibrous tumour: a retrospective study.
Stacchiotti S; Libertini M; Negri T; Palassini E; Gronchi A; Fatigoni S; Poletti P; Vincenzi B; Dei Tos AP; Mariani L; Pilotti S; Casali PG
Eur J Cancer; 2013 Jul; 49(10):2376-83. PubMed ID: 23566418
[TBL] [Abstract][Full Text] [Related]
13. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
Guérin O; Formento P; Lo Nigro C; Hofman P; Fischel JL; Etienne-Grimaldi MC; Merlano M; Ferrero JM; Milano G
J Cancer Res Clin Oncol; 2008 Jan; 134(1):51-7. PubMed ID: 17593391
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Stacchiotti S; Saponara M; Frapolli R; Tortoreto M; Cominetti D; Provenzano S; Negri T; Dagrada GP; Gronchi A; Colombo C; Vincenzi B; Badalamenti G; Zuco V; Renne SL; Collini P; Morosi C; Dei Tos AP; Bello E; Pilotti S; Casali PG; D'Incalci M; Zaffaroni N
Eur J Cancer; 2017 May; 76():84-92. PubMed ID: 28284173
[TBL] [Abstract][Full Text] [Related]
15. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.
Park MS; Patel SR; Ludwig JA; Trent JC; Conrad CA; Lazar AJ; Wang WL; Boonsirikamchai P; Choi H; Wang X; Benjamin RS; Araujo DM
Cancer; 2011 Nov; 117(21):4939-47. PubMed ID: 21480200
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
[TBL] [Abstract][Full Text] [Related]
17. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Cardoso F; Canon JL; Amadori D; Aldrighetti D; Machiels JP; Bouko Y; Verkh L; Usari T; Kern KA; Giorgetti C; Dirix L
Breast; 2012 Dec; 21(6):716-23. PubMed ID: 23022045
[TBL] [Abstract][Full Text] [Related]
18. Activity of sunitinib in patients with advanced neuroendocrine tumors.
Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience.
Levard A; Derbel O; Méeus P; Ranchère D; Ray-Coquard I; Blay JY; Cassier PA
BMC Cancer; 2013 Mar; 13():109. PubMed ID: 23496996
[TBL] [Abstract][Full Text] [Related]
20. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
